UK markets closed
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • FTSE 250

    22,931.66
    +14.61 (+0.06%)
     
  • AIM

    1,234.19
    -7.18 (-0.58%)
     
  • GBP/EUR

    1.1800
    -0.0061 (-0.51%)
     
  • GBP/USD

    1.3760
    -0.0036 (-0.26%)
     
  • BTC-GBP

    44,541.32
    -125.90 (-0.28%)
     
  • CMC Crypto 200

    1,453.34
    -49.69 (-3.31%)
     
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • DOW

    35,677.02
    +73.94 (+0.21%)
     
  • CRUDE OIL

    83.98
    +1.48 (+1.79%)
     
  • GOLD FUTURES

    1,793.10
    +11.20 (+0.63%)
     
  • NIKKEI 225

    28,804.85
    +96.27 (+0.34%)
     
  • HANG SENG

    26,126.93
    +109.40 (+0.42%)
     
  • DAX

    15,542.98
    +70.42 (+0.46%)
     
  • CAC 40

    6,733.69
    +47.52 (+0.71%)
     

Global $2.9 Billion Clinical Trial Supplies Markets to 2028

·2-min read

Dublin, Oct. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Clinical Trial Supplies Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.

The global clinical trial supplies market is expected to reach USD 2.9 billion by 2028 and is expected to witness growth at 6.0% CAGR owing to the Increasing volume of clinical trial studies coupled with the growing complexity in conduction of these trials are the primary driver of the industry.

Furthermore, geographic expansion and development of Information Technology (IT) to facilitate higher integration and smooth performance of activities are other vitally impacting parameters.

Over the next eight years, the clinical trials and pharmaceutical industry is anticipated to continue steady growth, thereby promoting the high requirement of clinical trial supplies.

U.S and Canada are home to majority of clinical trials which are conducted in this region. No language barrier is one of the major factors for the preference of this region for majority of clinical trials, as English language is widely spoken in this region.

Major CRO's and biopharmaceutical companies have their hub in this region and with advancement in technology the demand for efficient supplies is increasing and the region is expected to dominate the clinical trial supplies market over the forecast period.

Clinical Trial Supplies Market Report Highlights

  • On the basis of clinical phase, the market is anticipated to be dominated by Phase III in 2025. The presence of large number of molecules estimated to reach Phase III by 2020 is the primary factor responsible for this prediction.

  • By services, storage and distribution is anticipated to witness the fastest growth at a CAGR of over 7.0%.

  • Key end-users of this industry are pharmaceuticals, and biologics. Biologics are expected to witness fastest growth owing to the increasing research in the field of genetics and biotechnology such as development of nanoparticle-based drug delivery systems.

  • In terms of therapeutic use or clinical indication, oncology dominates the market. The highest research activity as of 2016 is being performed for this indication, which in turn is expected to drive the market.

Market Dynamics

Market Driver Analysis

  • Expansion of clinical trial sites

  • Growing R&D in biologics and biosimilars

  • Advancements in supply chain technology

  • Increase in comparator sourcing

Market Restraint Analysis

  • Presence of stringent regulatory policies

  • High possibility of counterfeiting of drugs

Few of the industry players include

  • Almac Group

  • Biocair

  • Catalent, Inc.

  • KLIFO

  • Movianto (Walden Group)

  • PCI Pharma Services

  • Sharp

  • Thermo Fischer Scientific, Inc.

  • Marken

  • Parexel International Corporation

For more information about this report visit https://www.researchandmarkets.com/r/udx4qx


CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting